
PRCT Stock Forecast & Price Target
PRCT Analyst Ratings
Bulls say
PROCEPT BioRobotics Corp has demonstrated a consistent growth trajectory in system utilization, experiencing an average increase of approximately 6.1% per quarter over the past six quarters. The company has committed to prudent financial management by curtailing the growth of operating expenses to half the rate of top-line growth, positioning itself for improved profitability. Additionally, management has expressed confidence in its product pipeline, anticipating a record number of system placements in the upcoming quarter, with recent placements surpassing previous guidance despite a challenging macroeconomic backdrop.
Bears say
PROCEPT BioRobotics Corp has seen a significant decline in share value, down approximately 54% year-to-date, despite its ability to exceed its own revenue guidance. The company faces multiple fundamental challenges, including a decrease in demand for capital equipment, reduced usage of handpieces by customers, intensified competition, and potential changes in reimbursement policies for its key therapy, Aquablation. These factors contribute to a negative outlook, as they are likely to dampen sales projections and investor sentiment moving forward.
This aggregate rating is based on analysts' research of PROCEPT BioRobotics Corp and is not a guaranteed prediction by Public.com or investment advice.
PRCT Analyst Forecast & Price Prediction
Start investing in PRCT
Order type
Buy in
Order amount
Est. shares
0 shares